BioWorld. Link to homepage.
BioWorld
BioWorld Science
BioWorld Asia
Data Snapshots
Biopharma
Medical technology
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Med-tech outlook 2026
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Sunday, March 15, 2026
Home
»
Newsletters
» BioWorld Science
BioWorld Science
July 8, 2009
View Archived Issues
Glutamate receptor antagonists have beneficial effects in model of Batten disease / News in Context
Read More
Phase III trials show improved sleep maintenance with doxepin
Read More
Phase I and II studies find Quadramet-docetaxel combination safe, active in prostate cancer
Read More
Alcon discontinues development of anecortave acetate in IOP after phase II trial
Read More
Phase II and III studies detail Acurox tolerability and analgesic efficacy
Read More
Full study results show OGX-011 meets requirements for further evaluation in prostate cancer
Read More
Celgene files NDA in Japan for Revlimid for multiple myeloma
Read More
Revotar to initiate phase IIa study of bimosiamose
Read More
FDA reviews Oxford Biomedica's phase III TRIST study of TroVax in renal cancer
Read More
Spectrum receives complete response letter from the FDA for Zevalin sBLA in NHL
Read More
Allos completes recruitment into phase IIb clinical trial of pralatrexate in advanced NSCLC
Read More
Novel guanylate cyclase activators emerge from GlaxoSmithKline R&D
Read More
Novel radiosensitizers claimed by K. Marcinkowski University of Medical Sciences
Read More
Palau Pharma patents histamine H4 receptor antagonists
Read More
ZSTK-474 inhibits angiogenesis in vitro and in vivo
Read More
Phase II data on ASA-404 in non-small cell lung cancer published
Read More
GTx initiates phase I clinical trial of GTx-758 for advanced prostate cancer
Read More
Pharmasset nominates PSI-938 as development candidate for HCV infection
Read More
Lexicon begins phase II clinical trial of LX-1032 in carcinoid syndrome
Read More
Repros provides update on clinical development of Proellex
Read More
Rexahn completes enrollment in phase IIa clinical trial of Serdaxin in MDD
Read More
FDA and King meet to discuss complete response letter regarding NDA for Remoxy
Read More
Inhibiton Therapeutics changes name to AlumiFuel Power
Read More
Kineta acquires exclusive commercial rights to Airmid's portfolio of therapeutic compounds
Read More
Presidio advances HCV inhibitor PPI-461 toward clinical development, IND-enabling studies under way
Read More
